Skip to main content
Premium Trial:

Request an Annual Quote

Attana Gets CE-IVD Mark for Analyzer, SARS-CoV-2 Antibody Assay

NEW YORK — Swedish biosensor developer Attana said on Tuesday that it has received CE-IVD marking for an immunoassay designed to detect antibodies against SARS-CoV-2, as well as for its Attana Cell 250 analyzer instrument.

The test is designed for the qualitative and semiquantitative measurement of immunoglobulin G against SARS-CoV-2 in serum. The company said that it is also pursuing the CE mark for versions of the test that use blood from finger pricks and plasma.

According to Attana, the analyzer enables the study of molecular interactions among proteins, DNA, and carbohydrates, as well as interactions with cultured cells. It is based on a technology, called quartz crystal microbalance, involving chips that contain quartz surfaces to measure changes in mass on a molecular level.

"During the summer and autumn, we will continue to perform a large number of analyses to, among other things, look at the effect of different vaccines and immune responses against different SARS-CoV-2 variants," Attana CEO Teodor Aastrup said in a statement. "In the coming months we also look forward to further commercializing our offering together with our distribution partners ensuring a successful market introduction of our diagnostic products."